• Source: Tefibazumab

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.
It was developed by Inhibitex.




See also


MSCRAMM (microbial surface components recognizing adhesive matrix molecules)




References

Kata Kunci Pencarian:

• Tefibazumab
• Clumping factor A
• MSCRAMM
• List of therapeutic monoclonal antibodies
• List of compounds with carbon numbers 50+
• List of drugs: Te
• ZMapp